key: cord-0691650-lvx9qwkk
authors: Aziz, Hafsa; Fatima, Shazia; Iqbal, Huma; Faheem, Mohammad
title: Recent Advances in Molecular diagnosis curbing the COVID-19
date: 2020-06-06
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.06.004
sha: 648840e17aa58a0a64ad5a1d322f438d9b228bce
doc_id: 691650
cord_uid: lvx9qwkk

• FDA has approved number of molecular tests for emergency use to address the pandemic confronting the world. • Broad testing will help to identify infected person, enabling proper quarantining, treatment and control. • No comparative analytical information is available about tests approved for emergency use. • This is a summary of FDA emergency use authorization(EUA) recommended nucleic acid diagnostic modalities.

WHO assigned name SARS-CoV-2 to virus causing Corona Virus Disease whichemerged in Wuhan city of Hubei province. It causes acute febrile illness with respiratory distress syndrome (ARDS). In 21 st century SARS-CoV-2 emerged as highly pathogenic corona virus for humans after SARS and MERS. World health organization declaredCOVID-19 outbreak a public health emergency of international concern on 30 of January 2020 (WHO, 2020; Tang et al., 2020; Wu and McGoogan, 2020) .The genome of coronavirus and its phylogenetic analysis indicate that it placed in distinct clad from other human β corona virus which caused SARS and MERS. On 28th April 2020 SARS-CoV-2 has spread to 213 countries. It infected more than 2million people and resulted in 193825 deaths globally. The exact number of infected people with SARS-CoV-2 is not known, as many asymptomatic cases go undetected (Kobayashi et al., 2020) . From the study of Diamond Princes cruise ship cases, the estimate reported 17.9% asymptomatic cases (Mizumoto et al., 2020) .Therefore asymptomatic individuals are infectious like symptomatic individuals and transmit the disease further. In the absence of vaccine and proper treatment, currently available efficient lever to reduce the transmission of SARS-COV-2 is to identify and isolate persons who are contagious .

The availability of specific and sensitive assays for the detection of the virus are essential for accurate diagnosis of affected cases, assessment of the extent of the outbreak, monitoring of intervention strategies and surveillance studies.FDA approved a number of molecular tests for emergency use to address the pandemic confronting the world (FDA, 2020). Broad testing will help identify the infected, allowing proper quarantining, treatment and control of its spread. This study gives a brief of FDA-Emergency Use Only recommended nucleic acid diagnostic modalities along with the limit of detection, target gene, type of sample and name of kits and developer details (Table 1) .

Nucleic acid detection technologies available for the detection of SARS-CoV-2 are RT-PCR and sequencing. The use of high throughput sequencing techniques is limited due to equipment dependency and cost. RT-PCR routinely used for the detection of SARS-CoV-2, acts as a gold standard platform because of its high sensitivity (Corman et al., 2020) . Different types of sampling techniques are used for detection include throat swab, nasopharyngeal swab, bronchoalveolar lavage fluid, sputum and endotracheal aspirates. Nasopharyngeal sample ismost commonly used sampling technique (Zou et al., 2020) .However bronchoalveolar lavage fluid, sputum endotracheal aspirates may have greater sensitivity than upper respiratory track samples (Wang et al., 2020) .Improper sampling technique may lead to false negative results. False negativity may be minimized by using flocked swab as it enhance the collection and release of cellular material and preferred those swab who have plastic or aluminium shaft. Sample transportation is another risk factor that contributes in false negativity of infectious sample. Collected samples undergo RNA extraction followed by RT-PCR for target detection. Three types of strategies have been described for target detection) single gene target assayii) double gene target assay iii) and multiplex assay.

The sensitivity of RT-PCR varies greatly, depending upon the target region of the virus used for amplification. Variation in the detection rate of some kits was observed but none of the assays showed cross-reactivity with other respiratory (corona) viruses (van Kasteren et al., 2020) . Commercially available assays no longer reported result in copies of viral RNA per milliliter (Table 1) To compare their reported sensitivity/limit of the assay results have been equalized into copies /mL. RT-PCR Kit for Detecting SARS-2019 of m/s BGI Genomics and Panther Fusion SARS-CoV-2 of m/s Hologic, both targets open reading frame ORF 1ab gene but difference in detection limit of the assays is noted. The former has 100-150 copies/mL and later detects in 100 copies/mL. Similarly, nine assays have targeting nucleocapsid (N) gene. Sensitivity of these kits range from 40copies/mL on BD MAX System S to 10^5 copies/mL on m/s GenMark ePlex instrument.CDC has developed real-time PCR assays used for SARS-COV-2.This has primers and probes targeting two region N1& N2 of viral nucleocapsid gene and human RNAase P gene as an internal control that ensure successful RNA extraction. The assay has analytical sensitivity of500copies/ mL (Zhen et al., 2020) . Primer design COVID-19 Genesig Real-Time PCR assay targeting polypeptide RdRp gene has also been developed (Table 1 (a) ). Among PCR assays that target two gene, Abbott Realtime SARS-CoV-2 m2000 RT System uses a combination of N and RdRp gene while four other assays target ORFlab gene in combination with nucleocapsid (N), structural (S) and envelope (E) genes. The detection limit of these assays ranges from20 copies/mL to 500 copies/mL (Table 1 (b) ).

Although, Realtime RT PCR is a predominant method for detection of all types of Coronavirus, including SARS CoV-2, the availableRealtime RT PCR kits have failed to detect the virus at early stages and give false negative results (Rothe et al., 2020) . The rapidly mutating nature of coronaviruses also demands a more accurate method for detection. Thus, multiplex Realtime RT-PCR systems using multiple genes (combinations of ORF lab gene, N gene, S gene and MS2 (Coat protein), RdRp gene) simultaneously amplified and tested has been developed. This may play important role in avoiding false negative results. The sensitivity of these assays ranges from 10 GCE/reaction (Genomic Copy Equivalents) (400copies/mL) by TaqPath TM COVID-19 Combo Kit from m/s Applied Biosystemsto 2500 GCE/reaction (5000 copies/mL) by NxTAGCoV Extended Panel Assay. QIAstat-Dx Respiratory 2019-nCoV Panel also gives a favorable sensitivity (500copies/mL) by multitarget detection of SARS CoV-2 (Table 1( c) .

Variation in the detection rate of some kits was observed but none of the assays showed cross-reactivity with other respiratory (corona) viruses.

The intensive testing for SARS-CoV-2 infection will help to identify infected and quarantining at appropriate time curb the spread of infection. The information on all the parameters provides an insight to both laboratories and clinical teams to identify the correct suitable platform. This will help them make informed decisions on use of kit, based on their need for accurate diagnosis of patients suffering from novel human corona virus Amidst the pandemic situation, it is now imperative to develop assays, which can be deployed easily in developing and underdeveloped countries, remote locations, and decentralized laboratory systems as well.

All authors do not have any conflict of interest including any financial, personal or other relationships with other people or organizations of submitted work.

All authors contributed equally to the design and writing of this article.

None.

The study was approved by the ethics review boards of the Nuclear Medicine, Oncology and Radiotherapy Institute. 

World Health Organization Director-General's remarks at the media briefing on 2019-nCoV on 11

Emergence of a novel coronavirus causing respiratory illness from Wuhan

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Communicating the risk of death from novel coronavirus disease (COVID-19). Multidisciplinary Digital Publishing Institute

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22

FDA. Coronavirus Disease (COVID-19) updates from FDAI.Coronavirus Disease

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Detection of SARS-CoV-2 in different types of clinical specimens

Comparison of seven commercial RT-PCR diagnostic kits for COVID-19

Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens

Transmission of 2019-nCoV infection from an asymptomatic contact in Germany